Clinical aspects of platelet inhibitors and thrombus formation.
The platelet, once thought to be solely involved in clot formation, is now known to be a key mediator in various others processes such as inflammation, thrombosis, and atherosclerosis. Supported by the wealth of evidence from clinical trials demonstrating their benefits in patient outcomes, antiplatelet agents have become paramount in the prevention and management of various diseases involving the cardiovascular, cerebrovascular, and peripheral arterial systems. Despite being among the most widely used and studied classes of medical therapies, new discoveries regarding important clinical aspects and properties of these agents continue to be made. As our understanding of platelet biology expands, more effective and safer novel therapies continue to be developed. The use of more refined agents in conjunction with a better understanding of their effects will further the ability to provide more optimized care on an individual basis.
Meadows
Telly A
TA
Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH 44195, USA.
Bhatt
Deepak L
DL
D001241:Aspirin / Q000627:therapeutic use; D050197:Atherosclerosis / Q000209:etiology / Q000517:prevention & control; D001792:Blood Platelets / Q000502:physiology; D002318:Cardiovascular Diseases / Q000517:prevention & control; D000077407:Cilostazol; D000077144:Clopidogrel; D004176:Dipyridamole / Q000627:therapeutic use; D004351:Drug Resistance; D006801:Humans; D010421:Pentanoic Acids / Q000627:therapeutic use; D010973:Platelet Adhesiveness / Q000187:drug effects; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors; D058919:Purinergic P2 Receptor Antagonists; D011725:Pyridines / Q000627:therapeutic use; D015607:Stents / Q000009:adverse effects; D013777:Tetrazoles / Q000627:therapeutic use; D013927:Thrombosis / Q000209:etiology* / Q000517:prevention & control; D013931:Thromboxanes / Q000037:antagonists & inhibitors; D013988:Ticlopidine / Q000031:analogs & derivatives / Q000627:therapeutic use
D010421:Pentanoic Acids; D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D058919:Purinergic P2 Receptor Antagonists; D011725:Pyridines; D013777:Tetrazoles; D013931:Thromboxanes; D004176:Dipyridamole; D000077144:Clopidogrel; D000077407:Cilostazol; D013988:Ticlopidine; C060219:ridogrel; D001241:Aspirin